Literature DB >> 25173639

Expression of P-glycoprotein in human retinoblastoma and its clinical significance.

Sumita Sethi1, Manzoor Ahmad Malik, Sandeep Goswami, Parul Saxena, Arpna Srivastava, Seema Kashyap, Neelam Pushker, Mandeep Singh Bajaj, Sameer Bakhshi, Jasbir Kaur.   

Abstract

Retinoblastoma is the most common malignant intraocular tumor of childhood. Drug resistance and relapses are major problems with chemotherapy, which is regarded as the mainstay of globe preserving treatment in retinoblastoma. P-glycoprotein (P-gp) expression has been reported to be associated with chemoresistance and poor prognosis in various malignancies. We analyzed P-gp expression in retinoblastoma specimens, enucleated either primarily or after neoadjuvant chemotherapy by immunohistochemistry and immunoblotting, and correlated with the histopathological findings. Variables were statistically analyzed by Fischer's exact and chi-square tests. Tumor tissues were collected from enucleated eyes of 24 children. Fifteen of these were primarily enucleated (group I), and nine (group II) had received chemotherapy prior to enucleation. P-gp was expressed in 4/15 (26.7 %) eyes in group I and in 5/9 (55.6 %) eyes in group II. P-gp was highly expressed in group II as compared to group I. There was no correlation between P-gp expression and tumor differentiation, invasion, or laterality. In conclusion, there was markedly high expression of P-gp in eyes with retinoblastoma enucleated after chemotherapy. This may possibly play a role in chemoresistance or it may be that chemotherapy might have induced high expression. These findings may have important implications for the treatment of retinoblastoma patients but need further prospective investigations in a larger patient population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25173639     DOI: 10.1007/s13277-014-2116-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

Review 1.  Emerging strategies for the treatment of retinoblastoma.

Authors:  William F Deegan
Journal:  Curr Opin Ophthalmol       Date:  2003-10       Impact factor: 3.761

2.  Drug resistance in clinical oncology and hematology. Introduction.

Authors:  G A Fisher; B I Sikic
Journal:  Hematol Oncol Clin North Am       Date:  1995-04       Impact factor: 3.722

3.  Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation.

Authors:  M J Greenwald; L C Strauss
Journal:  Clin Cancer Res       Date:  1997-03       Impact factor: 12.531

4.  Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma.

Authors:  D L Friedman; B Himelstein; C L Shields; J A Shields; M Needle; D Miller; G R Bunin; A T Meadows
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

5.  Histopathological features and P-glycoprotein expression in retinoblastoma.

Authors:  João Pessoa Souza Filho; Zelia Maria S Correa; Alexandre N Odashiro; Anamaria Baptista Coutinho; Maria Cristina Martins; Clélia Maria Erwenne; Miguel N Burnier
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

Review 6.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

Authors:  Hilary Thomas; Helen M Coley
Journal:  Cancer Control       Date:  2003 Mar-Apr       Impact factor: 3.302

7.  Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines.

Authors:  H S Chan; M D Canton; B L Gallie
Journal:  Anticancer Res       Date:  1989 Mar-Apr       Impact factor: 2.480

8.  Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network.

Authors:  S Huet; J P Marie; N Gualde; J Robert
Journal:  Cytometry       Date:  1998-12-15

9.  Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.

Authors:  H S Chan; P S Thorner; G Haddad; V Ling
Journal:  J Clin Oncol       Date:  1990-04       Impact factor: 44.544

10.  Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma.

Authors:  S Krishnakumar; K Mallikarjuna; N Desai; A Muthialu; N Venkatesan; A Sundaram; V Khetan; M P Shanmugam
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

View more
  5 in total

1.  Expression of multidrug-resistance associated proteins in human retinoblastoma treated by primary enucleation.

Authors:  Li-Juan Tang; Li-Jun Zhou; Wen-Xin Zhang; Jian-Yan Lin; Yong-Ping Li; Hua-Sheng Yang; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

Review 2.  Nanocarriers for ocular drug delivery: current status and translational opportunity.

Authors:  Srividya Gorantla; Vamshi Krishna Rapalli; Tejashree Waghule; Prem Prakash Singh; Sunil Kumar Dubey; Ranendra N Saha; Gautam Singhvi
Journal:  RSC Adv       Date:  2020-07-24       Impact factor: 4.036

Review 3.  Systemic side effects of eye drops: a pharmacokinetic perspective.

Authors:  Andre Farkouh; Peter Frigo; Martin Czejka
Journal:  Clin Ophthalmol       Date:  2016-12-07

4.  The expression and clinical significance of murine double minute 2, lysosome-associated membrane protein 1, and P-glycoprotein in pediatric acute lymphoblastic leukemia.

Authors:  Zhuoyu Wen; Hui Li; Juan Zhang
Journal:  Transl Pediatr       Date:  2020-10

5.  Early Mechanisms of Chemoresistance in Retinoblastoma.

Authors:  Michelle G Zhang; Jeffim N Kuznetsoff; Dawn A Owens; Ryan A Gallo; Karthik Kalahasty; Anthony M Cruz; Stefan Kurtenbach; Zelia M Correa; Daniel Pelaez; J William Harbour
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.